Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.7, Iss.6, 1997-06, pp. : 631-639

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The therapeutic potential of PDE4 inhibitors

By Dyke H.J. Montana J.G.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1327-1327

Informa Healthcare

Access to resources Recommend Favorite

The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation

By Kruuse C. Rybalkin S.D. Khurana T.S. Jansen-Olesen I. Olesen J. Edvinsson L.

European Journal of Pharmacology, Vol. 420, Iss. 1, 2001-05 ,pp. : 55-65

Elsevier

Access to resources Recommend Favorite

Therapeutic Potential of Selective PDE Inhibitors in Asthma

By Schudt C. Gantner F. Tenors H. Hatzelmann A.

Pulmonary Pharmacology & Therapeutics, Vol. 12, Iss. 2, 1999-04 ,pp. : 123-129

Academic Press

Access to resources Recommend Favorite

Update on the therapeutic potential of PDE4 inhibitors

By Montana John G Dyke Hazel J

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 1, 2002-01 ,pp. : 1-13

Informa Healthcare

Access to resources Recommend Favorite

PDE5 Inhibitors and their Applications

Current Medicinal Chemistry, Vol. 17, Iss. 24, 2010-08 ,pp. : 2564-2587

Bentham Science Publishers

Access to resources Recommend Favorite